Schede di attività / 2012 - CPO

Prevenzione secondariaCentro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in PiemonteScheda: 3.006NEW TECHNOLOGIES FOR CERVICAL CANCER SCREENING (NTCC) WORKING GROUP. Accuracy of liquid-basedversus conventional cytology: overall results of the new technologies for cervical cancer screening randomisedcontrolled trial. BMJ 2007; 335: 28-31. (e-published 21 May 2007 doi: 10.1136/bmj.39196.740995.BE)• GIORGI ROSSI P, SEGNAN N, ZAPPA M, NALDONI C, ZORZI M, CONFORTINI M, MERITO M, RONCO G AND THENTCC WORKING GROUP. The impact of new technologies in cervical cancer screening: results of therecruitment phase of a large randomised controlled trial from a public health perspective. Int J Cancer 2007;121: 2729-34.• RONCO G, BREZZI S, CAROZZI F, DALLA PALMA P, GIORGI-ROSSI P, MINUCCI D, NALDONI C, SEGNAN N,ZAPPA M, ZORZI M, CUZICK J AND THE NTCC STUDY GROUP. The New Technologies for Cervical CancerScreening randomised controlled trial. An overview of results during the first phase of recruitment. GynecolOncol 2007; 107: S230-S232.• RONCO G, SEGNAN N. Human papillomavirus testing for primary cervical cancer screening (invitedcomment). Lancet 2007; 370: 1740-2.• RONCO G, GIORGI-ROSSI P, CAROZZI F, CONFORTINI M, DALLA PALMA P, DEL MISTRO A, GILLIO-TOS A,MINUCCI D, NALDONI C, RIZZOLO R, SCHINCAGLIA P, VOLANTE R, ZAPPA M, ZORZI M, CUZICK J, SEGNAN N andthe New Technologies for Cervical Cancer screening (NTCC) Working Group. Results at Recruitment from aRandomized Controlled Trial Comparing Human Papillomavirus Testing Alone to Conventional Cytology as thePrimary Cervical Cancer Screening Test. J Natl Cancer Inst 2008; 100: 492-501.• CUZICK J, ARBYN M, SANKARANARAYANAN R, TSU V, RONCO G, MAYRAND MH, DILLNER J, MEIJER CJL.Overview of human papillomavirus-based and other novel options for cervical cancer screening in developedand developing countries. Vaccine 2008; 26S: K29-K41. ( IF: 3.377)• CAROZZI F, CONFORTINI M, DALLA PALMA P, DEL MISTRO A, GILLIO-TOS A, DE MARCO L, GIORGI-ROSSI P,PONENTANI G, ROSSO S, SANI C, SINTONI C, SEGNAN N, CUZICK J, RIZZOLO R, RONCO G and the NewTechnologies for Cervical Cancer screening (NTCC) working group. Use of p16-INK4A overexpression toincrease the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlledtrial. Lancet Oncol 2008; 9: 937-45.• MEIJER CJ, BERKHOF J, CASTLE PE, HESSELINK AT, FRANCO EL, RONCO G, ARBYN M, BOSCH FX, CUZICK J,DILLNER J, HEIDEMAN DA, SNIJDERS PJ. Guidelines for human papillomavirus DNA test requirements forprimary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-20.• RODRIGUES DE ARAUJO M, DE MARCO L, SANTOS CF, FISHER RUBINA-BULLEN IR, RONCO G, PENNINI I,VIZZINI L, MERLETTI F, GILLIO-TOS A. GP5+/6+ -SYBR Green methodology for simultaneous screening andquantification of Human Papillomavirus. J Clin Virol 2009;45:90-95.• ARBYN M, RONCO G, CUZICK J, WENTZENSEN N, CASTLE PE. How to evaluate emerging technologies incervical screening? Int J. Cancer 2009;125:2489-96.• RONCO G, ARBYN M, SEGNAN N. Cervical screening according to age and HPV status (Editorial). BMJ2009;339:b3005• LYNGE E, ANTILLA A, ARBYN M, SEGNAN N, RONCO G. What's next? Perspectives and future needs of cervicalscreening in Europe in the era of molecular testing and vaccination. Eur J Cancer. 2009 ;45:2714-21.• ARBYN M, RONCO G, MEIJER CJLM, NAUCLER P. Trials comparing cytology with HPV screening (letter). LancetOncol. 2009;10:935-6.• RONCO G, GIORGI-ROSSI P, CAROZZI F, CONFORTINI M, DALLA PALMA P, DEL MISTRO A, GHIRINGHELLO B,GIRLANDO S, GILLIO-TOS A, DE MARCO L, NALDONI C, PIEROTTI P, RIZZOLO R, SCHINCAGLIA P, ZORZI M,ZAPPA M, SEGNAN N, CUZICK J and the New Technologies for Cervical Cancer screening (NTCC) WorkingGroup. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervicalintraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010 ;11:249-257.• Ronco G on behalf of the NTCC working group. Author’s Reply. Lancet Oncol 2010;11:510-11.• Ronco G & Meijer CJLM. HPV Screening: Available data and recommendations for clinical practice. CurrentCancer Therapy Reviews 2010;6:104-9• Serraino D, Ronco G, Franceschi S. Infections and cancer: the contribution of European research in recentprogresses. Epidemiol Prev. 2010;34:56-61• Franceschi S, Ronco G. The prevention of cervical cancer in HIV-infected women (Editorial). AIDS.2010;24:2579-80.• Franceschi S, Denny L, Irwin KL, Jeronimo J, Lopalco PL, Monsonego J, Peto J, Ronco G, Sasieni P, Wheeler CM.Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer. 2011 Jan 4. [Epub ahead of print PMID:21207409]• Giorgi-Rossi P, Franceschi S, Ronco G. Human papilloma virus (HPV) prevalence and accuracy of HPV testingto detect high-grade cervical intraepithelial neoplasia. Int J Cancer 2012;15:1387-94.• Ronco G, Franceschi S, Segnan N. HPV16 and HPV18 genotyping in cervical cancer screening (invitedcomment). Lancet Oncol 2011;12:831-2.• Ronco G, Meijer CJL, Cuzick, Giorgi-Rossi P, Peto J, Segnan N and Dillner J. Human papillomavirus testing toscreen for cervical cancer (letter). Ann Intern Med 2012;156:604-5.LINEE GUIDA• Arbyn M, Dillner J,Schenk U, Nieminen P, Weiderpass E, Da Silva GD, Jordan J, Ronco G, McGoogan E, PatnickJ, Sparen P, Herbert A, Bergeron C. Chapter 3. Methods for screening and diagnosis. In: Arbyn M, Anttila A,Jordan J, .Ronco G, Schenck U, Segnan N, Wiener H, eds. European guidelines for quality assurance on cervicalcancer screening. 2nd edition . Luxembourg: Office for Official Publications of the European Communities,2008.92